ANNALS OF ONCOLOGY肿瘤学年鉴
ANNALS OF ONCOLOGY(英文缩写 ANN ONCOL),ISSN 0923-7534,eISSN 1569-8041,中文译名:肿瘤学年鉴 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 51.769 | Q1 |
| 2022 | 50.500 | Q1 |
| 2023 | 56.700 | Q1 |
| 2024 | 65.400 | Q1 |
| 2025 | 80.400 | Q1 |
ANNALS OF ONCOLOGY 最新收录文献
-
2. Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.
2. II期KEYNOTE-427研究中，一线帕博利珠单抗单药治疗晚期肾细胞癌的最终结果及应答和长期结局的预测生物标志物PMID:日期:2026-09-29Previous results from the single-arm, phase II KEYNOTE-427 study showed antitumor activity with first-line pembrolizumab monotherapy in advanced clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC). We report results of the final efficacy and safety analyses and exploratory, predictive biomarker analysis of KEYNOTE-427. Eligible participants had histologically confirmed locally advanced, recurrent, or metastatic ccRCC (cohort A) or nccRCC (cohort B) with or without sarcomatoid features, measurable disease per RECIST v1.1, and no prior systemic therapy for advanced RCC. The primary end point was objective response rate (ORR) per RECIST v1.1 by blinded independent central review. Prespecified biomarker objectives were to evaluate the association of clinical outcomes with a T-cell-inflamed gene expression profile (TcellGEP), programmed cell death ligand 1 combined positive score (PD-L1 CPS), RCC driver gene mutations, and circulating tumor DNA (ctDNA; cohort A). After a median (range) follow-up of 61.1 months (54.7-65.5) in cohort A and 56.7 months (47.9-64.0) in cohort B, ORRs were 36.4% and 26.7%, respectively. Continuous TcellGEP was positively associated with ORR in cohort A (P=0.0208) and cohort B (P=0.0021). Continuous PD-L1 CPS was positively associated with ORR (P=0.0195) and progression-free survival (PFS; P=0.0307) in cohort A and ORR (P <0.0001), PFS (P=0.0002), and overall survival (OS; P=0.0014) in cohort B. RCC driver gene mutations showed no consistent patterns with ORR in either cohort. In cohort A, participants with detectable ctDNA at baseline had a shorter OS than participants with a ctDNA-negative status (median: 30.5 months [95% CI 18.1-56.4] vs 53.7 months [28.7-not reached]). These results show that pembrolizumab is a highly active agent in ccRCC and nccRCC. Insights from the comprehensive analysis of RCC tumor molecular components and ctDNA may facilitate progress toward effective, biomarker-driven precision treatment in advanced RCC.
-
5. Predict. Support. Act? DeepComp and post-operative risk in gastric cancer.
5. 预测。支持。行动？DeepComp与胃癌术后风险PMID:日期:2026-09-18该文献暂无摘要。
-
6. Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.
PMID:日期:2026-09-17Premenopausal women with hormone receptor-positive (HR+)/HER2-negative early breast cancer represent a clinically distinct population, characterized by more aggressive tumor biology, unique survivorship concerns, and complex treatment decision-making. Although evidence from dedicated trials and subgroup analyses is available, management remains challenging because data are heterogeneous, evolving, and often extrapolated from broader populations that include predominantly postmenopausal women. Adjuvant endocrine therapy, with the addition of CDK4/6 inhibitors in selected higher-risk patients, remains the cornerstone of treatment; however major uncertainties persist regarding the optimal use of ovarian function suppression, the interpretation of genomic assays to inform chemotherapy decisions, the selection of candidates for extended endocrine therapy, and the management of adherence, treatment-related toxicities, pregnancy-related issues, and survivorship concerns. Here, we synthesize current evidence across these domains and propose a pragmatic clinical framework to support individualized treatment strategies and optimize care for this population in the contemporary therapeutic landscape.